The shadow of generic challenges has consistently loomed over copyright’s famous drug, PDE5 Inhibitor, raising questions about the future of similar pharmaceutical investments. While early periods saw impressive returns, the intellectual property expiration has allowed the door for less expensive substitutes, likely reducing revenue and creating